Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes.
This is mainly attributed to the high rates of dyslipidemia among diabetic patients which is believed to be one of the major factors accounting for the high percentage of deaths among diabetics due to cardiovascular disease (CVD) .
The differences in the lipid profile between diabetics (especially type 2 diabetics) and nondiabetics account for the increased CVD risk .
Potency is thought to correlate to tissue permeability as the more lipophilic statins such as atorvastatin are thought to enter endothelial cells by passive diffusion, as opposed to hydrophilic statins such as pravastatin and rosuvastatin which are taken up into hepatocytes through OATP1B1 (organic anion transporter protein 1B1)-mediated transport.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To investigate the efficacy and the safety of the three most commonly prescribed statins (rosuvastatin, atorvastatin, and pravastatin) for managing dyslipidemia among diabetic patients in Qatar. This retrospective observational population-based study included 350 consecutive diabetes patients who were diagnosed with dyslipidemia and prescribed any of the indicated statins between September 2005 and September 2009.
Essentially, T2DM lipid profiles consist of elevations in triglyceride (TG) levels (2 mmol/L) and reductions in high-density lipoprotein cholesterol (HDL-C).
While low-density lipoproteins cholesterol (LDL-C) concentration levels are normal, the particles are denser and smaller in size, which is believed to enhance their atherogenic potential .
The responses of atorvastatin and its metabolites for atorvastatin and its metabolites.
The intra- and inter-day precision variations were between 3.3% and 13.9%.
The matrix effects of plasma were in the range of 102.7–105.5% for atorvastatin and 90.3–96.6% for atorvastatin lactone.
This method was successfully applied in clinical studies of atorvastatin in coronary artery disease patients.